| Benjamin J Fogal, OD | |
|
9801 Dupont Ave S Ste 200, Bloomington, MN 55431-3200 | |
| (952) 888-5800 | |
| (952) 567-6156 |
| Full Name | Benjamin J Fogal |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 19 Years |
| Location | 9801 Dupont Ave S Ste 200, Bloomington, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730174822 | NPI | - | NPPES |
| P00362877 | Other | MN | RAILROAD MEDICARE |
| 769412100 | Medicaid | MN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152WC0802X | Optometrist - Corneal And Contact Management | 3019 (Minnesota) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Minnesota Eye Consultants, Pa | 4284524539 | 33 |
News Archive
Marcadia Biotech Inc. today announced that it has initiated a Phase 1 clinical trial of MAR701, a novel dual agonist of the incretin hormone receptors for glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP). Marcadia plans to initially develop this compound as a treatment for type 2 diabetes with once-weekly dosing. The Phase 1 trial will evaluate MAR701 in healthy volunteers at escalating dose levels.
A new study appearing in the latest issue of Epilepsia shows that a new drug called Eslicarbazepine (ESL) shows promise as a treatment for epilepsy patients whose symptoms remain uncontrolled with existing medications.
Using the example of the fruit fly, a team of biologists led by Prof. Dr. Andrew Straw has identified patterns in the genetic activity of brain cells and taken them as a basis for drawing conclusions about the structure of the brain.
Researchers at the University of Illinois at Chicago College of Nursing have received a four-year grant to determine whether exercise can shorten recovery time for patients who undergo high-dose chemotherapy and stem cell transplantation.
The Viennese biotech company Affiris is today taking stock of the progress achieved to date in its clinical Alzheimer's vaccination programme. All the Alzheimer's patients treated so far as part of the toxicological trials have tolerated the treatment extremely well. As a result, Affiris is among the leading international centres in the race to develop the first causal immunotherapy for Alzheimer's disease.
› Verified 6 days ago
| Provider Name | Minnesota Eye Consultants, Pa |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1508839879 PECOS PAC ID: 4284524539 Enrollment ID: O20040318001449 |
News Archive
Marcadia Biotech Inc. today announced that it has initiated a Phase 1 clinical trial of MAR701, a novel dual agonist of the incretin hormone receptors for glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP). Marcadia plans to initially develop this compound as a treatment for type 2 diabetes with once-weekly dosing. The Phase 1 trial will evaluate MAR701 in healthy volunteers at escalating dose levels.
A new study appearing in the latest issue of Epilepsia shows that a new drug called Eslicarbazepine (ESL) shows promise as a treatment for epilepsy patients whose symptoms remain uncontrolled with existing medications.
Using the example of the fruit fly, a team of biologists led by Prof. Dr. Andrew Straw has identified patterns in the genetic activity of brain cells and taken them as a basis for drawing conclusions about the structure of the brain.
Researchers at the University of Illinois at Chicago College of Nursing have received a four-year grant to determine whether exercise can shorten recovery time for patients who undergo high-dose chemotherapy and stem cell transplantation.
The Viennese biotech company Affiris is today taking stock of the progress achieved to date in its clinical Alzheimer's vaccination programme. All the Alzheimer's patients treated so far as part of the toxicological trials have tolerated the treatment extremely well. As a result, Affiris is among the leading international centres in the race to develop the first causal immunotherapy for Alzheimer's disease.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Benjamin J Fogal, OD 9801 Dupont Ave S, Suite 425, Bloomington, MN 55431-3100 Ph: (952) 567-6092 | Benjamin J Fogal, OD 9801 Dupont Ave S Ste 200, Bloomington, MN 55431-3200 Ph: (952) 888-5800 |
News Archive
Marcadia Biotech Inc. today announced that it has initiated a Phase 1 clinical trial of MAR701, a novel dual agonist of the incretin hormone receptors for glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP). Marcadia plans to initially develop this compound as a treatment for type 2 diabetes with once-weekly dosing. The Phase 1 trial will evaluate MAR701 in healthy volunteers at escalating dose levels.
A new study appearing in the latest issue of Epilepsia shows that a new drug called Eslicarbazepine (ESL) shows promise as a treatment for epilepsy patients whose symptoms remain uncontrolled with existing medications.
Using the example of the fruit fly, a team of biologists led by Prof. Dr. Andrew Straw has identified patterns in the genetic activity of brain cells and taken them as a basis for drawing conclusions about the structure of the brain.
Researchers at the University of Illinois at Chicago College of Nursing have received a four-year grant to determine whether exercise can shorten recovery time for patients who undergo high-dose chemotherapy and stem cell transplantation.
The Viennese biotech company Affiris is today taking stock of the progress achieved to date in its clinical Alzheimer's vaccination programme. All the Alzheimer's patients treated so far as part of the toxicological trials have tolerated the treatment extremely well. As a result, Affiris is among the leading international centres in the race to develop the first causal immunotherapy for Alzheimer's disease.
› Verified 6 days ago
Dr. Frantz Junior Pierre Toussaint, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 8600 Nicollet Ave S, Bloomington, MN 55420 Phone: 952-541-2800 | |
Neda Tahvilian, OD Optometrist Medicare: Medicare Enrolled Practice Location: 9801 Dupont Ave S Ste 200, Bloomington, MN 55431 Phone: 952-888-5800 | |
Dr. Danford William Davis, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 9117 Lyndale Ave S, Bloomington, MN 55420 Phone: 952-835-1235 Fax: 952-835-0534 | |
Shayna Mellesmoen, OD Optometrist Medicare: Medicare Enrolled Practice Location: 9117 Lyndale Ave S, Bloomington, MN 55420 Phone: 952-835-1235 | |
Dr. Lori Louise Mowbray, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1650 W 82nd St, #800, Bloomington, MN 55431 Phone: 952-844-0844 Fax: 952-844-0810 | |
Dr. Scott D Hadden, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 715 E 78th St, Bloomington, MN 55420 Phone: 952-854-2262 Fax: 952-854-5493 | |
Michael Daniel Scheidt, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 9801 Dupont Ave S Ste 200, Bloomington, MN 55431 Phone: 952-888-5800 |